One Biosciences
Operating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | €15.0m | Series A | |
| Total Funding | 000k | ||
Related Content
One Biosciences operates in the biotechnology sector, focusing on the development of RNA-based therapies aimed at precision medicine. The company leverages advanced RNA technologies to create personalized healthcare solutions, targeting specific genetic profiles to treat various diseases. One Biosciences primarily serves healthcare providers, pharmaceutical companies, and research institutions. The company operates in the global biotechnology market, which is characterized by rapid innovation and high growth potential. Its business model revolves around research and development, clinical trials, and eventual commercialization of its RNA-based therapies. Revenue is generated through partnerships, licensing agreements, and sales of proprietary treatments. The company is led by a team of experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and finance, ensuring a strong foundation for growth and innovation.
Keywords: RNA-based therapies, precision medicine, personalized healthcare, biotechnology, genetic profiles, clinical trials, pharmaceutical partnerships, healthcare innovation, advanced RNA technologies, global market.